Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.
What happened
FDA inspected Woodbine Products Company Inc.'s drug manufacturing facility in Medina, Ohio, from February 9 to 13, 2026. Investigators found the company did not test each incoming lot of components (glycerin, propylene glycol, ethanol) for identity, used nonpharmaceutical-grade propylene glycol, and did not test high-risk ingredients for diethylene glycol (DEG) or ethylene glycol (EG) or ethanol for methanol. FDA also found the company had never validated its manufacturing or cleaning processes, that a water system appeared unsuitable for its intended use, and that the quality unit failed to provide proper oversight.
What FDA found
The company did not run at least one identity test on each incoming lot of components such as glycerin, propylene glycol, and ethanol before using them to make drugs.
21 CFR 211.84(d)(1)It used nonpharmaceutical-grade propylene glycol and did not test high-risk ingredients for diethylene glycol or ethylene glycol, or its ethanol for methanol.
21 CFR 211.84(d)(1)It never validated the processes used to make its OTC drugs and did not validate cleaning of equipment shared across products.
21 CFR 211.100(a)The water system used in manufacturing appears unsuitable for its intended use and was not routinely tested for microbial counts and contamination identity.
21 CFR 211.100(a)The quality unit did not ensure adequate laboratory specifications, testing of each batch before release, a stability program, or complete batch production records.
21 CFR 211.22The quality unit lacked adequate written responsibilities and procedures, and did not follow the procedures it had.
21 CFR 211.22(d)
What FDA wants
FDA tells the company to correct the violations promptly, to provide within 30 calendar days DEG and EG test results on retained samples (and alcohol impurity results) plus a risk assessment covering products still within expiry, including customer notifications and recalls if needed. The company must respond in writing within 15 working days, and FDA recommends engaging a qualified CGMP consultant.
Who should pay attention
- brands and repackagers that buy OTC topical or ethanol-based drugs from this contract manufacturer
- retailers and distributors selling the affected OTC products
- suppliers and vendors providing glycerin, propylene glycol, or ethanol to drug makers
This is a summary. Read the original letter on fda.gov.